Zivo Bioscience, Inc. (ZIVO) Executive Compensation
Zivo Bioscience, Inc. (ZIVO) is a publicly traded company on the OTC, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ZIVO
CIK: 1101026
Exchange: OTC
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
BDO USA, P.C.
Auditor SinceSince 12/31/2023 12:00:00 AM
Lead Engagement PartnerStephanie Wolf
Audit LocationTroy, Michigan, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-04-24 | 2026-04-17 | 4 Filing | 0001213900-26-047650 | View SEC Doc Filr Page |
| EFFECT | 2026-04-01 | — | EFFECT Filing | 9999999995-26-001036 | View SEC Doc Filr Page |
| 15-12G | 2026-03-31 | — | 15-12G | 0001654954-26-002990 | View SEC Doc Filr Page |
| S-8 POS | 2026-03-31 | — | S-8 | 0001654954-26-002988 | View SEC Doc Filr Page |
| POS AM | 2026-03-31 | — | POS AM | 0001654954-26-002983 | View SEC Doc Filr Page |
| 8-K | 2026-03-30 | 2026-03-26 | FORM 8-K | 0001654954-26-002928 | View SEC Doc Filr Page |
| 4 | 2026-03-03 | 2026-02-27 | PRIMARY DOCUMENT | 0001654954-26-001833 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-02-27 | — | SCHEDULE 13D/A Filing | 0001213900-26-021894 | View SEC Doc Filr Page |
| 4 | 2026-02-17 | 2026-02-12 | 4 Filing | 0001213900-26-016803 | View SEC Doc Filr Page |
| 4 | 2026-02-12 | 2026-02-10 | PRIMARY DOCUMENT | 0001654954-26-001157 | View SEC Doc Filr Page |
| 4 | 2026-01-28 | 2026-01-26 | PRIMARY DOCUMENT | 0001654954-26-000652 | View SEC Doc Filr Page |
| 4 | 2026-01-28 | 2026-01-26 | PRIMARY DOCUMENT | 0001654954-26-000651 | View SEC Doc Filr Page |
| 4 | 2026-01-27 | 2026-01-14 | PRIMARY DOCUMENT | 0001654954-26-000631 | View SEC Doc Filr Page |
| 4 | 2026-01-27 | 2026-01-14 | PRIMARY DOCUMENT | 0001654954-26-000630 | View SEC Doc Filr Page |
| 3 | 2025-12-29 | 2025-12-19 | 3 | 0001193125-25-335502 | View SEC Doc Filr Page |
| 8-K | 2025-12-23 | 2025-12-19 | FORM 8-K | 0001654954-25-014296 | View SEC Doc Filr Page |
| 4 | 2025-12-02 | 2025-11-28 | PRIMARY DOCUMENT | 0001641073-25-000004 | View SEC Doc Filr Page |
| 10-Q | 2025-11-14 | 2025-09-30 | FORM 10-Q | 0001654954-25-013095 | View SEC Doc Filr Page |
| 4 | 2025-10-20 | 2025-10-13 | 4 Filing | 0001213900-25-100376 | View SEC Doc Filr Page |
| 4 | 2025-10-14 | 2025-10-10 | PRIMARY DOCUMENT | 0001654954-25-011774 | View SEC Doc Filr Page |
| 4 | 2025-10-09 | 2025-10-08 | PRIMARY DOCUMENT | 0001654954-25-011614 | View SEC Doc Filr Page |
| 4 | 2025-10-06 | 2025-10-02 | PRIMARY DOCUMENT | 0001654954-25-011515 | View SEC Doc Filr Page |
| 4 | 2025-10-06 | 2025-10-02 | PRIMARY DOCUMENT | 0001654954-25-011513 | View SEC Doc Filr Page |
| 4 | 2025-10-06 | 2025-10-02 | PRIMARY DOCUMENT | 0001654954-25-011510 | View SEC Doc Filr Page |
| 4 | 2025-10-02 | 2025-09-30 | PRIMARY DOCUMENT | 0001641073-25-000003 | View SEC Doc Filr Page |